Skip to main content

ResTORbio stock plummets on late-stage drug failure

Boston biopharma startup resTORbio Inc. fell as it approached the finish line, reporting Friday that its most advanced drug candidate failed in the last leg of testing.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.